SequelSEC

Biofrontera Inc. BFRI

Pharmaceutical Preparations · CIK 0001858685 · Fiscal year ends 1231

AnnualQuarterlyTTM
Revenue
$46.18M
Fiscal year ended 2026-06-30
Operating income
-$6.56M
Fiscal year ended 2026-06-30
Free cash flow
-$7.93M
Fiscal year ended 2026-06-30

Valuation, from the filing

Public float$6.90MMarket value of stock held by non-affiliates, as stated on the cover page for 2025-06-30
Float per share$0.59Float divided by shares outstanding in the same filing. A floor under the share price on that date, not the price itself.
Float / revenue0.2×A lower bound on the multiple, because affiliate holdings are excluded.
Float / equity0.7×A lower bound on the multiple, because affiliate holdings are excluded.

Every figure here is drawn from the 10-K cover page and the statements behind it, so each one traces to a filing. Public float counts only stock held by non-affiliates, which makes these floors rather than estimates: a high multiple is conclusive, a low one may mean cheap or may mean closely held. The float was measured on 2025-06-30, not today, and each multiple below it uses the figures for the fiscal year ending 2025-12-31 — the year that filing covered.

How this compares in its industry

Percentile among the Pharmaceutical Preparations filers on this site, highest value first. A high percentile means a large figure, which is good for a margin and not for leverage — the ranking says where the company sits, not whether that is where it should be.

MeasureReportedPercentile
CapEx / revenue0.0%4th
SBC / revenue2.3%12th
R&D / revenue8.9%13th
Current ratio1.52x21th
Operating margin-27.2%68th
Net margin-25.3%65th
FCF margin-32.0%60th
Revenue YoY growth11.7%59th

Biofrontera Inc. (BFRI) reported revenue of $46.18M and net income of -$6.36M for the fiscal year ended 2026-06-30. This page shows 1 annual period of income statement, balance sheet and cash flow figures normalized from Biofrontera Inc.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Pharmaceutical Preparations.

Income

Biofrontera Inc. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Revenue$46.18M
Cost of revenueUnavailable
Gross profitUnavailable
Operating income-$6.56M
Net income-$6.36M
Research & development$2.99M
Weighted-average diluted sharesUnavailable
Pretax income-$6.34M
Income tax expenseUnavailable
Diluted EPSUnavailable
Selling, general & administrative$39.19M
General & administrative$21.98M
Selling & marketingUnavailable

Balance

Biofrontera Inc. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Cash & equivalents$4.66M
Total assets$24.06M
Current assets$12.44M
Total liabilities$18.11M
Current liabilities$10.54M
Total equity incl. NCI$5.96M
Temporary (mezzanine) equityUnavailable
Inventory$1.10M
Accounts receivable$5.54M
GoodwillUnavailable
Long-term debtUnavailable
Accounts payableUnavailable

Cash flow

Biofrontera Inc. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Operating cash flow-$7.93M
Capital expenditures$3.00K
Investing cash flow$3.00M
Financing cash flowUnavailable
Net change in cash-$2.58M
Stock-based compensation$1.13M
Common dividends paidUnavailable
Common share repurchasesUnavailable
Depreciation & amortizationUnavailable

Derived

Biofrontera Inc. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Free cash flow-$7.93M
Gross marginUnavailable
Operating margin-14.2%
FCF margin-17.2%
SBC / revenue2.4%
Current ratio1.18x
Revenue YoY growth17.8%
Net margin-13.8%
R&D / revenue6.5%
CapEx / revenue0.0%
Long-term debt / equityUnavailable
Effective tax rateUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open BFRI in the interactive workspace to inspect any figure back to its filing.

Source filings

25-NSE · Filed 2026-10-30View SEC filing
10-Q · Filed 2026-08-13View SEC filing
10-Q · Filed 2026-05-14View SEC filing
10-K · Filed 2026-03-19View SEC filing
10-Q · Filed 2025-11-12View SEC filing
10-Q · Filed 2025-08-13View SEC filing

Companies in the same industry

AAGH AARD ABBV ABCL ABEO ABT ABUS ABVC ACAD ACET ACRS ACRV

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.